全球腎癌治療市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計腎癌治療市場將從 2025 年的 74.7 億美元成長到 2034 年的 126.5 億美元，2026 年至 2034 年的複合年成長率為 6.02%。

由於腎細胞癌發生率不斷上升以及對有效腫瘤治療的需求日益成長，全球腎癌治療市場正經歷穩定成長。腎癌是全球最常見的癌症之一，標靶治療和免疫療法的進步顯著改善了治療效果。人們對癌症早期檢測意識提升以及獲得先進醫療服務的機會增加，也促進了該市場的擴張。

製藥公司正大力投資研發，以推出能提高存活率並減少副作用的創新治療方法。標靶治療和免疫查核點抑制劑為腎癌患者提供了更精準的治療選擇，正日益普及。此外，新藥臨床試驗的擴展和監管核准的推進也促進了各個地區市場的成長。

展望未來，由於癌症研究和個人化醫療的不斷進步，全球腎癌治療市場預計將顯著成長。生技公司正在探索新的藥物組合和免疫療法，以提高治療效果。隨著醫療保健支出不斷成長以及對腫瘤治療日益重視，腎癌治療市場預計在未來幾年將迎來顯著成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球腎癌治療市場：依癌症類型分類

• 市場分析、洞察與預測
• 腎臟細胞癌（RCC）
• 移行細胞癌
• 威爾姆氏腫瘤
• 腎臟肉瘤

第5章：全球腎癌治療市場：依療法分類

• 市場分析、洞察與預測
• 標靶治療
• 免疫療法
• 化療
• 其他治療方法

第6章 全球腎癌治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 血管新生抑制劑
• 單株抗體
• mTOR抑制劑
• 細胞激素免疫療法（IL-2）
• 其他藥物類別

第7章 全球腎癌治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 靜脈注射
• 皮下注射

第8章 全球腎癌治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 實體店面
• 電子商務

第9章 全球腎癌治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Active Biotech AB
  • Amgen Inc
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co. Ltd
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc
  • GSK Plc
  • Helsinn Healthcare SA
  • Johnson & Johnson Services Inc
  • Merck & Co. Inc
  • Novartis AG

The Kidney Cancer Drugs Market size is expected to reach USD 12.65 Billion in 2034 from USD 7.47 Billion (2025) growing at a CAGR of 6.02% during 2026-2034.

The Global Kidney Cancer Drugs Market is experiencing steady growth due to the increasing prevalence of renal cell carcinoma and the rising demand for effective oncology treatments. Kidney cancer remains one of the most commonly diagnosed cancers worldwide, and advancements in targeted therapies and immunotherapies are significantly improving treatment outcomes. Growing awareness regarding early cancer detection and improved access to advanced healthcare facilities are also contributing to the expansion of this market.

Pharmaceutical companies are investing heavily in research and development to introduce innovative therapies that offer improved survival rates and reduced side effects. Targeted drugs and immune checkpoint inhibitors are becoming increasingly popular as they provide more precise treatment options for kidney cancer patients. Additionally, the expansion of clinical trials and regulatory approvals for novel drugs is supporting market growth across various regions.

Looking ahead, the Global Kidney Cancer Drugs Market is expected to witness substantial expansion due to continued advancements in cancer research and personalized medicine. Biotechnology companies are exploring new drug combinations and immunotherapy approaches to improve treatment effectiveness. With increasing healthcare spending and growing emphasis on oncology care, the market for kidney cancer drugs is projected to grow significantly in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Cancer Type

• Renal Cell Carcinoma (RCC)
• Transitional Cell Cancer
• Wilms Tumor
• Renal Sarcoma

By Therapy

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Other Therapies

By Drug Class

• Angiogenesis Inhibitors
• Monoclonal Antibodies
• mTOR Inhibitors
• Cytokine Immunotherapy (IL-2)
• Other Drug Classes

By Route of Administration

• Oral
• Intravenous
• Subcutaneous

By Distribution Channel

• Hospital Pharmacy
• Brick and Mortar
• E-commerce

COMPANIES PROFILED

• Active Biotech AB, Amgen Inc, Astellas Pharma Inc, AstraZeneca PLC, Bayer AG, BristolMyers Squibb Company, Eisai Co Ltd, Exelixis Inc, F HoffmannLa Roche Ltd, Genentech Inc, GSK plc, Helsinn Healthcare SA, Johnson Johnson Services Inc, Merck Co Inc, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL KIDNEY CANCER DRUGS MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Cancer Type
• 4.2. Renal Cell Carcinoma (RCC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Transitional Cell Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Wilms Tumor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Renal Sarcoma Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL KIDNEY CANCER DRUGS MARKET: BY THERAPY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapy
• 5.2. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL KIDNEY CANCER DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Class
• 6.2. Angiogenesis Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. mTOR Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Cytokine Immunotherapy (IL-2) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL KIDNEY CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL KIDNEY CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Brick and Mortar Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. E-commerce Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL KIDNEY CANCER DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Cancer Type
  • 9.2.2 By Therapy
  • 9.2.3 By Drug Class
  • 9.2.4 By Route Of Administration
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Cancer Type
  • 9.3.2 By Therapy
  • 9.3.3 By Drug Class
  • 9.3.4 By Route Of Administration
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Cancer Type
  • 9.4.2 By Therapy
  • 9.4.3 By Drug Class
  • 9.4.4 By Route Of Administration
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Cancer Type
  • 9.5.2 By Therapy
  • 9.5.3 By Drug Class
  • 9.5.4 By Route Of Administration
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Cancer Type
  • 9.6.2 By Therapy
  • 9.6.3 By Drug Class
  • 9.6.4 By Route Of Administration
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL KIDNEY CANCER DRUGS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Active Biotech AB
  • 11.2.2 Amgen Inc
  • 11.2.3 Astellas Pharma Inc
  • 11.2.4 AstraZeneca PLC
  • 11.2.5 Bayer AG
  • 11.2.6 Bristol-Myers Squibb Company
  • 11.2.7 Eisai Co. Ltd
  • 11.2.8 Exelixis Inc
  • 11.2.9 F. Hoffmann-La Roche Ltd
  • 11.2.10 Genentech Inc
  • 11.2.11 GSK Plc
  • 11.2.12 Helsinn Healthcare SA
  • 11.2.13 Johnson & Johnson Services Inc
  • 11.2.14 Merck & Co. Inc
  • 11.2.15 Novartis AG